Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2021 | Tafasitamab for R/R DLBCL

Ulrich Jäger • 28 Jun 2021
EHA 2021
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Tafasitamab

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the use of tafasitamab, a CD19-targeted monoclonal antibody, and immune checkpoint inhibitors for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies 1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia 1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries 1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy 0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL 3:25
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Manali Kamdar • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals